期刊文献+

补肾强督方治疗强直性脊柱炎患者259例临床研究 被引量:25

Clinical Study on Bushen Qiangdu Recipe for Treatment of 259 Cases of Ankylosing Spondylitis
下载PDF
导出
摘要 目的探讨补肾强督方治疗强直性脊柱炎(AS)的临床疗效与安全性。方法本研究共入选259例门诊和住院患者,予补肾强督方治疗,每日1剂,早晚分服,疗程6个月,治疗前后评价如下疗效指标患者健康综合评分(BAS-G)、疾病活动指数(BASDAI)、功能指数(BASFI)、全身痛Likert四级评分、脊柱痛Likert四级评分、晨僵时间、医生总体评价、枕墙距、指地距、颌柄距、胸廓活动度、Schober征、脊柱活动度、“4”字试验、血沉(ESR)、C反应蛋白(CRP),并观察血常规、尿常规、肝肾功能等药物安全性指标。结果259例患者经用补肾强督方治疗6个月后,除枕墙距、颌柄距无明显改变外,其余指标均有显著改善。259例患者均未出现血常规、尿常规改变及肝肾功能损害。结论补肾强督方对AS有较好疗效,且安全可靠。 Objective:To explore clinical therapeutic effect and safety of Bushen Qiangdu Recipe on ankylosing spondylitis (AS). Methods: 259 out-patients and in-patients enrolled were treated with Bushen Qiangdu Recipe for 6 months,one dose each day for oral administration in morning and night. BAS-G,BASDAI,BASFI,Likert' 4-grade score of spinal pain, Likert' 4-grade score of whole body pain, duration of morning stiffness, evaluation of doctor, the occiput-wall distance, the finger-floor distance, the mandible-stermum distance,chest expansion, Schober' test ,the range of spinal movement,Gaenslen's sign, ESR, CRP, blood and urine routine examination,renal and hepatic functions were detected before and after treatment. Results:Significant improvement was observed in all indexes except for the occiput-wall distance and the mandible-stermum distance ,and no adverse effect in blood and urine routine examination and renal and hepatic function was found. Conclusion: Bushen Qiangdu Recipe has therapeutic effect on ankylosing spondylitis.
出处 《中医杂志》 CSCD 北大核心 2006年第6期433-435,共3页 Journal of Traditional Chinese Medicine
基金 中日友好医院院级课题(2001023)
关键词 脊柱炎 强直性/中医药疗法 @补肾强督方 Spondylitis,ankylosing/TCM therapy @Bushen Qiangdu Recipe
  • 相关文献

参考文献6

  • 1Jones SD,Steiner A,Garrett SL,et al.The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).Br J Rheumatol,1996,35 (1):66~71.
  • 2Garrett S,Jenkinson T,Kennedy LG,et al.A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index.J Rheumatol,1994,21 (12):2286 ~2291.
  • 3Calin A,Garrett S,Whitelock H,et al.A new approach to defining functional ability in ankylosing sponkylitis:the development of the Bath Ankylosing Spondylitis Functional Index.J Rheumatol,1994,21 (12):2281~2285.
  • 4Huang F,Gu J,Zhao W,et al.One-year open-label trial of thalidomide in ankylosing spondylitis.Arthritis Rheum,2002,47 (3):249 ~ 254.
  • 5庄俊汉,叶志中,张丽君,汪迅,钟力.反应停治疗强直性脊柱炎的临床研究[J].中国药物与临床,2002,2(6):363-366. 被引量:9
  • 6黄烽,古洁若,赵伟,朱剑,张江林,余德恩.反应停治疗强直性脊柱炎的临床与实验研究[J].中华风湿病学杂志,2002,6(5):309-315. 被引量:75

二级参考文献13

  • 1Rowland TL,McHugh SM,Deighton J,et al.Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.Immunopharmacology,1998,40:11-20.
  • 2Laasila K,Leirisalo-Repo M.Side effects of sulphasalazine in patients with rheumatic diseases of inflammatory bowel disease.Scand J Rheumatol,1994,23:338-340.
  • 3Clegg DO,Reda DJ,Weisman MH.Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis:a Department of Veterans Affairs Cooperative Study.Arthritis Rheum,1996,39:2004-2012.
  • 4Bennett PH,Berch TA.New York symposium on population studies in the rheumatic disease:new diagnostic criteria.Bull Rheum Dis,1967,17:453-458.
  • 5Rowland TL,McHugh SM,Deighton J.Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide:comparisons with dexamethasone.Immunol Lett,1999,68:325-332.
  • 6Breban M,Gombert B,Amor B.Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis.Arthritis Rheum,1999,42:580-581.
  • 7赵伟,黄烽.强直性脊柱炎治疗新进展[J].中国新药杂志,2001,10(7):485-488. 被引量:19
  • 8黄烽,杨春花.强直性脊柱炎临床及免疫发病机制的研究进展[J].中国免疫学杂志,2001,17(6):281-285. 被引量:61
  • 9古洁若,黄烽,余得恩.cDNA芯片技术在强直性脊柱炎研究中的初步应用[J].中华医学杂志,2001,81(17):1030-1034. 被引量:23
  • 10罗绍凯,李娟,洪文德,周振海,邹外一.沙利度胺对骨髓瘤患者免疫学的影响[J].中国新药杂志,2001,10(9):683-685. 被引量:5

共引文献80

同被引文献205

引证文献25

二级引证文献169

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部